We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 16. | 장 마감 후 (AMC) | $1.28 | — | — | $12.53B | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.76 | — | — | $10.36B | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $2.38 | — | — | $30.98B |
Consensus PT $118.32 · 25 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 27. | BTIG | — | 의견 유지 | Buy → Buy | — | BTIG: Buy |
| 2026. 04. 20. | Barclays | — | 의견 유지 | Overweight → Overweight | — | Barclays: Overweight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $1.44 | — | — | $20.34B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 6,388,828 | $655.94B | 0.56% | — | 신규 편입 |
| 2 | SOROS FUND MANAGEMENT LLC | SOROS FUND MANAGEMENT LLC | 44,750 | $4.59B | 0.08% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Stored first · Google News · Yahoo Finance (English)
Abbott Laboratories stock (US0028241000): Insider activity stays in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Insider activity stays in focus AD HOC NEWS
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? - Yahoo Finance
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? Yahoo Finance
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 富途牛牛
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know Yahoo Finance